A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Bristol Myers Squibb’s experimental drug admilparant has shown promise in a late-stage clinical trial involving people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes irreversible scarring and gradually worsens breathlessness.

The pharmaceutical company announced on October 12 that the lower dose of the drug significantly slowed the decline in lung function compared to a placebo over 52 weeks. However, the higher dose did not meet the trial’s primary goal, raising questions about the treatment’s effects subject to dosage.

The Phase 3 ALOFT-IPF trial enrolled 1,255 patients and evaluated two doses of admilparant, 60 mg and 120 mg, taken twice daily. The study compared both doses with a placebo. Its primary goal was measuring changes in forced vital capacity (FVC) from the start of treatment to Week 52.

FVC measures the amount of air a person can forcefully exhale after taking a deep breath. A decline in this measure can indicate worsening lung function.

According to Bristol Myers Squibb, the 60 mg dose demonstrated a statistically significant benefit over placebo. The 120 mg dose also slowed the decline in lung function, but the difference did not reach statistical significance.

The company said the drug was generally well tolerated at both doses. Also, the treatment discontinuation due to adverse events remained low compared to placebo. Detailed trial results are yet to be presented.

What Is Idiopathic Pulmonary Fibrosis?

Also read: Can Delhi’s Air Pollution Increase GI Cancer Risk? Doctors Report Patients As Young As 15

IPF is a chronic lung disease in which lung tissue becomes progressively scarred and stiff. As the scarring advances, the lungs become less efficient at transferring oxygen into the bloodstream, making everyday activities increasingly difficult.

The disease is described as idiopathic because its precise cause is unknown. Symptoms commonly include persistent breathlessness, a dry cough and fatigue. The condition can progress unpredictably, and the damage caused by fibrosis is generally irreversible.

Existing antifibrotic treatments can slow the loss of lung function, but they do not eliminate established scarring or cure the disease. This leaves a need for additional treatments that can delay progression.

About Admilparant

Admilparant, also known as BMS-986278, is an oral drug designed to block the lysophosphatidic acid receptor 1 (LPA1).

The LPA1 signalling pathway is involved in processes linked to pulmonary fibrosis, including inflammation, tissue injury and the activation of cells that produce scar tissue. By blocking this receptor, admilparant is intended to interfere with mechanisms that contribute to the progression of lung scarring.

The drug is being investigated as a first-in-class treatment that uses this approach in people with IPF and progressive pulmonary fibrosis.

“IPF remains one of the most complex and challenging lung diseases to treat, with unpredictable progression, irreversible scarring and a profound impact on patients’ daily lives,” said Fernando Martinez, chair of the ALOFT programme’s clinical steering committee and a professor of medicine at UMass Chan Medical School.

“These admilparant results represent an important advancement as there remains a need for therapies that are both effective and tolerable for patients living with IPF,” he added.

Bristol Myers Squibb said it would complete a comprehensive evaluation of the trial data and deal with regulatory authorities for submissions. The detailed findings are expected to be presented at a future meeting.

Pennsylvania has reported its sixth measles-related death of 2026, involving a 39-year-old woman in Franklin County. State health officials are reviewing the case as the outbreak continues to spread across the state.

The Franklin County Coroner’s Office said it investigated the woman’s death on October 10. In a statement released on October 12, the office said the case met Pennsylvania’s definition of a measles-associated death. The woman’s identity and further medical details have not been disclosed to protect her family’s privacy.

According to NBC News, a spokesperson for the coroner’s office said the woman was unvaccinated and that the “primary cause of death was a probable acute cardiac event due to possible complications of the measles.” The Pennsylvania Department of Health has launched a review of the reported death.

Pennsylvania Reports Sixth Measles-Related Death

The latest death comes as Pennsylvania continues to grapple with a substantial measles outbreak. State health department figures updated on October 9 recorded 1,136 cases across the state in 2026, among which 219 people required hospitalisation.

The first two deaths announced in the state in late August were infants, which were both in Lancaster County, which majority of cases are concentrated. A pregnant woman with measles went into labor a month early. The baby died shortly after birth. The other was a 6-week-old who had a rare genetic condition.

A 40-year-old woman with asthma and severe lung disease died in Jefferson County. An 18-year-old Mifflin County resident died “due to complications of measles,” specifically a rare and severe neurological condition that causes inflammation in the brain.

The Philadelphia Inquirer reported in early October that the fifth death occurred in a 20-year-old woman with a compromised immune system because of leukemia.

The vast majority of people diagnosed with measles are unvaccinated. According to the Pennsylvania Department of Health, less than 1% of cases there occurred in people who were fully vaccinated.

Also read: US Health Secretary Wants To Expand Vaccine Injury Reporting: Benefits And Risks Explained

Pennsylvania And The CDC Report Different Death Counts

Pennsylvania has classified six deaths as measles-associated this year, while the US Centers for Disease Control and Prevention has reported two measles-associated deaths.

The difference reflects the need for consistent definitions and review procedures. Pennsylvania defines a measles-associated death as one occurring within 30 days of symptom onset in a person with clinical evidence of measles and a positive laboratory test, provided the death is not due to an unrelated cause.

Additional information, including exposure history and medical records, may also be considered. The CDC and the Council of State and Territorial Epidemiologists have been working on standardised definition for classifying measles-related deaths.

Also read: Nearly 4,000 Measles Cases In US: CDC Director Says MMR Vaccine Is ‘Absolutely Safe’

Measles Death Prevention

Measles is a highly contagious viral infection that spreads through the air when an infected person coughs or sneezes. The virus can remain infectious in the air for up to two hours after the person has left.

Symptoms generally begin seven to 14 days after exposure, although they can take up to 21 days to appear. Early signs include high fever, cough, runny nose and red, watery eyes, followed by a characteristic rash.

Although many people recover, measles can cause serious complications, including pneumonia and encephalitis, or inflammation of the brain. Babies, young children and people with weak immune systems are vulnerable to severe measles complications.

Vaccination remains the most effective way to prevent measles and its complications. Two doses of the measles, mumps and rubella (MMR) vaccine are approximately 97% effective against measles.

Pennsylvania health authorities have been expanding vaccination clinics and outreach in affected communities. More than 53,000 MMR doses were administered across the state in September, according to the health department.

The Franklin County Coroner’s Office urged residents and healthcare professionals to follow public health guidance.

“We strongly encourage our medical community, first responders and the public to follow the precautions set forth by the PA Department of Health and Center for Disease Control,” the office said. “Caution and vigilance are key to our success in the treatment of this disease and its after affects.”

The deaths of two University of Mississippi students whose toxicology reports reportedly detected synthetic kratom-related substances have renewed concerns about the gas-station supplement and calls for a nationwide ban.

Kratom is banned in at least eight US states: Alabama, Arkansas, Connecticut, Indiana, Louisiana, Tennessee, Vermont and Wisconsin. Several others, including Iowa and Idaho, are considering restrictions.

What Happened In Mississippi?

Aidan Hamilton, 18, and Robert Strang, 20, died in separate incidents on September 21. Investigators found packaging associated with kratom-related products, including SMAX Pseudo-DHM, at both locations, according to court documents.

A defense attorney for one of two men accused of selling narcotics connected to at least one death told a Mississippi federal court that one student died from the combined effects of multiple substances, including cough syrup, while the other died from inhalation asphyxiation, Action News 5 reported.

Court records reportedly showed that both students had mitragynine pseudoindoxyl, MGM-15 and 7-hydroxymitragynine (7-OH) in their systems. However, the presence of these substances alone does not establish that they caused the deaths.

Kratom Use And Related Health Concerns Are Growing

Kratom comes from the leaves of the Mitragyna speciosa tree, native to Southeast Asia. Traditionally used for its stimulant and pain-relieving effects, it is now sold in the US as powders, capsules, teas and extracts.

US poison centers recorded 3,434 kratom exposure reports in 2025, up from 258 in 2015, according to CDC data.

Legislative efforts to restrict kratom have also intensified. An analysis by The Washington Post found that, among roughly 400 related bills considered across states, 108 proposed bans on kratom or related synthetic chemicals, while 258 focused on measures such as age limits, licensing and potency restrictions.

Can Kratom Be Addictive?

Kratom contains alkaloids, primarily mitragynine. At lower doses, it can increase alertness and energy; at higher doses, it can produce sedative and opioid-like effects by interacting with opioid receptors in the brain.

Regular use can lead to physical dependence. Withdrawal symptoms may include irritability, restlessness, muscle aches, fatigue and sweating.

The US Food and Drug Administration (FDA) says evidence suggests that some people develop substance use disorder after using kratom, although its potential for abuse has not been fully characterized in well-designed human studies.

Why Are Concentrated 7-OH Products Concerning?

7-hydroxymitragynine, or 7-OH, occurs naturally in trace amounts in kratom leaf. Some commercial products contain concentrated levels and are sold as tablets, gummies and drink shots.

The FDA has warned that these products have not been demonstrated to be safe or effective for any medical use. The American College of Medical Toxicology has highlighted concerns about opioid-like intoxication, respiratory depression, dependence and withdrawal.

Kratom-Related Hospitalizations Are Rising

According to a University of Virginia study, hospitalizations linked solely to kratom rose from 43 in 2015 to 538 in 2025.

Poison centers recorded 901 exposures involving 7-OH between January and June 2026, compared with 593 during all of 2025.

Although these figures highlight growing concerns, they do not establish that concentrated 7-OH products caused the increase in kratom-related hospitalizations.

Kratom is not an FDA-approved treatment for pain, opioid withdrawal or any other medical condition. Its long-term health effects remain incompletely understood.